Celeste Silveira

Celeste Silveira

Auto-generated profile, based on publicly available information

Celeste Silveira

Psychiatry Service, Psychiatry and Mental Health Clinic of São João University Hospital Center, Oporto, Portugal

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2019 in Psychiatry Investigation
Verified
Journal Article
Open access
PDF file
CSCeleste Silveira
Celeste Silveira
RGRenato Guedes
Renato Guedes
DMDiana Maia
Diana Maia
RCRosário Curral
Rosário Curral
RCRui Coelho
Rui Coelho
Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients' quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain's lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals' well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities.

17 June 2014 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
ABAntónio J. Bastos-Leite
António J. Bastos-Leite
GRGerard R. Ridgway
Gerard R. Ridgway
CSCeleste Silveira
Celeste Silveira
ANAndreia Norton
Andreia Norton
SRSalomé Reis
Salomé Reis
KFKarl Friston Friston
Karl Friston Friston
We report the first stochastic dynamic causal modeling (sDCM) study of effective connectivity within the default mode network (DMN) in schizophrenia. Thirty-three patients (9 women, mean age = 25.0 years, SD = 5) with a first episode of psychosis and diagnosis of schizophrenia—according to the Diagnostic and Statistic Manual of Mental Disorders, 4th edition, revised criteria—were studied. Fifteen healthy control subjects (4 women, mean age = 24.6 years, SD = 4) were included for comparison. All subjects underwent resting state functional magnetic resonance imaging (fMRI) interspersed with 2 periods of continuous picture viewing. The anterior frontal (AF), posterior cingulate (PC), and the left and right parietal nodes of the DMN were localized in an unbiased fashion using data from 16 independent healthy volunteers (using an identical fMRI protocol). We used sDCM to estimate directed connections between and within nodes of the DMN, which were subsequently compared with t tests at the between subject level. The excitatory effect of the PC node on the AF node and the inhibitory self-connection of the AF node were significantly weaker in patients (mean values = 0.013 and −0.048 Hz, SD = 0.09 and 0.05, respectively) relative to healthy subjects (mean values = 0.084 and −0.088 Hz, SD = 0.15 and 0.77, respectively; P < .05). In summary, sDCM revealed reduced effective connectivity to the AF node of the DMN—reflecting a reduced postsynaptic efficacy of prefrontal afferents—in patients with first-episode schizophrenia.

1 December 2014 in International Journal of Psychophysiology
Verified
Journal Article
Closed access
DPDiana R. Pereira
Diana R. Pereira
SCSusana Cardoso
Susana Cardoso
Fernando Ferreira-SantosFernando Ferreira-Santos
Fernando Ferreira-Santos
CFCarina Fernandes
Carina Fernandes
CRCassilda Cunha Reis
Cassilda Cunha Reis
JMJoão Marques-Teixeira
João Marques-Teixeira


1 January 2016 in Clinical Neurophysiology
Verified
Journal Article
Closed access
TPTiago O. Paiva
Tiago O. Paiva
PAPedro R Almeida
Pedro R Almeida
Fernando Ferreira-SantosFernando Ferreira-Santos
Fernando Ferreira-Santos
JVJoana B. Vieira
Joana B. Vieira
CSCeleste Silveira
Celeste Silveira
JMJoão Marques-Teixeira
João Marques-Teixeira

1 December 2012 in Journal of Nervous & Mental Disease
Verified
Journal Article
Closed access
CSCeleste Silveira
Celeste Silveira
JMJoão Marques-Teixeira
João Marques-Teixeira
ABAntónio José de Bastos-Leite
António José de Bastos-Leite
Schizophrenia is a very complex psychiatric disorder of unknown etiology, and there is controversy as to whether its name is even appropriate to describe the associated variety of clinical presentations and symptoms. Currently, the diagnosis is essentially based on clinical criteria. These enable a clinical profile to be recognized as encompassing positive symptoms, negative symptoms, disorganization of thinking and behavior, cognitive impairment, mood abnormalities, motor abnormalities, chronic clinical course, and incomplete remissions. The concept has evolved during the past century, and schizophrenia is currently questioned as a single disease entity. Established diagnostic criteria do not mirror the heterogeneity of the disorder. A strategy to deal with clinical heterogeneity in schizophrenia is, perhaps, the adoption of a classification system based on dimensions and stages. An additional strategy to deal with etiological and pathophysiological heterogeneity is to try to identify biomarkers, namely, on the basis of intermediate phenotypes. Despite extensive biological research, the biomarkers for schizophrenia are still lacking.